UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.RTOG-0924Principal InvestigatorRoach III, Mack
PhaseIII (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.0924
TitleAndrogen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
ObjectiveDemonstrate that prophylactic neoadjuvant androgen deprivation therapy (NADT) and whole- pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) in patients with ““unfavorable”” intermediate risk or ““favorable”” high risk prostate cancer compared to NADT and high dose prostate and seminal vesicle (SV) radiation therapy (P + SV RT) using intensity modulated radiotherapy (IMRT) or EBRT with a high dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost
Key Eligibility* Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence * Clinically negative lymph nodes as established by imaging * No evidence of bone metastases (M0) on bone scan
Applicable Disease SitesProstate
Therapies InvolvedRadiotherapy
Participating InstitutionsMt. Zion : Romobia Hutchinson
Parnassus : Romobia Hutchinson
University of California San Francisco : Romobia Hutchinson
Eligibility DocumentRTOG-0924_CTGov_Eligibility_NCT01368588.doc
ContactRomobia Hutchinson Phone:415-353-4294